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Abstract
Periosteum is known to contain cells that, after isolation 
and culture-expansion, display properties of mesenchymal 
stromal/stem cells (MSCs). However, the equivalent cells 
have not been identified in situ mainly due to the lack of 
specific markers. Postnatally, stem cells are slow-cycling, 
long-term nucleoside-label-retaining cells. This study 
aimed to identify and characterise label-retaining cells 
in mouse periosteum in vivo. Mice received iodo-deoxy-
uridine (IdU) via the drinking water for 30 days, followed 
by a 40-day washout period. IdU+ cells were identified 
by immunostaining in conjunction with MSC and lineage 
markers. IdU-labelled cells were detected throughout the 
periosteum with no apparent focal concentration, and were 
negative for the endothelial marker von Willebrand factor 
and the pan-haematopoietic marker CD45. Subsets of IdU+ 
cells were positive for the mesenchymal/stromal markers 
vimentin and cadherin-11. IdU+ cells expressed stem cell 
antigen-1, CD44, CD73, CD105, platelet-derived growth 
factor receptor-α and p75, thereby displaying an MSC-like 
phonotype. Co-localisation was not detectable between IdU 
and the pericyte markers CD146, alpha smooth muscle actin 
or NG2, nor did IdU co-localise with β-galactosidase in a 
transgenic mouse expressing this reporter gene in pericytes 
and smooth muscle cells. Subsets of IdU+ cells expressed 
the osteoblast-lineage markers Runx2 and osteocalcin. The 
IdU+ cells expressing osteocalcin were lining the bone and 
were negative for the MSC marker p75. In conclusion, 
mouse periosteum contains nucleoside-label-retaining cells 
with a phenotype compatible with MSCs that are distinct 
from pericytes and osteoblasts. Future studies characterising 
the MSC niche in vivo could reveal novel therapeutic targets 
for promoting bone regeneration/repair.
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Introduction
Periosteum, the thin membranous tissue situated at the 
boundary between bone and the surrounding soft tissues, 
has long been known to be osteogenic. As early as 1867, 
the French surgeon Ollier reported that free periosteal 
grafts are able to produce bone (Ollier, 1867). It is 
now well-established that periosteum, in particular the 
cambium layer facing the bone, is a rich source of stem/
progenitor cells which play important roles in bone repair. 
Removal of the periosteum significantly diminishes the 
capacity for repair both in animal models (Ozaki et al., 
2000) and clinically (Gerstenfeld et al., 2003).
 Fibroblast-like cells can be isolated from periosteum 
that display properties of mesenchymal stromal/stem 
cells (MSCs), including clonogenicity, phenotypic marker 
expression, and ability to differentiate into osteoblasts, 
chondrocytes, and adipocytes (Nakahara et al., 1990; 
Nakahara et al., 1991; De Bari et al., 2001; De Bari 
et al., 2006). However, the equivalent cells have not 
been identified in vivo due to lack of specific markers to 
identify these cells in their native tissue. Therefore, many 
questions remain regarding the topography, phenotype, 
function and regulation of MSCs in periosteum and the 
niches they reside in. A full understanding of the biology 
of stem/progenitor cells in periosteum is critical for 
the development of improved protocols and discovery 
of novel pharmacological targets to prevent and treat 
fractures.
 Adult stem cells are conventionally considered 
as being slow-cycling cells. Hence, long-term label-
retaining assays and associated marker analyses have been 
successfully employed to identify stem cells in their own 
tissue environments, such as in the bulge of the hair follicle 
(Cotsarelis et al., 1990; Tumbar et al., 2004). We recently 
demonstrated that functional MSCs in mouse synovium 
are label-retaining cells (Kurth et al., 2011). Studies in the 
1960s using tritiated thymidine showed that periosteum 
also contains label-retaining cells (Tonna et al., 1960; 
Tonna and Cronkite et al., 1962; Tonna and Cronkite, 
1968). However, the phenotype of these cells was not fully 
determined due to lack of available phenotypic markers at 
that time. Long-term label-retaining cells are not limited 
to slow-cycling stem cells, but also include cells that, 
following labelling, undergo differentiation into a post-
mitotic mature phenotype. Hence, there is a requirement 
for marker analyses to identify label-retaining cells with 
an MSC phenotype in vivo. In this study, we performed a 
classical long-term nucleoside-analogue-retaining assay 
and determined the phenotype and topography of the 
label-retaining cells in periosteum by immunostaining 
for conventional MSC and lineage markers.
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Materials and Methods
Animals and nucleoside analogue administration
Animal experiments were approved by the UK Home 
Office and conducted in accordance with the Animals 
(Scientific Procedures) Act 1986 and the Home Office 
Code of Practice. Twenty-one-day-old male C57BL/6 mice 
and transgenic mice expressing the LacZ gene in pericytes 
and smooth muscle cells (Tidhar et al., 2001) received 
the artificial nucleoside iodo-deoxy-uridine (IdU; Sigma-
Aldrich, Gillingham, UK) with the drinking water for 30 
days at a concentration of 1 mg/mL. IdU administration 
was then stopped for the next 40 days (washout period), 
after which mice were killed.
Histological sample processing
Femora were dissected and fixed in 2 % paraformaldehyde 
and 0.05 % glutaraldehyde in PBS for 1 h at room 
temperature. After decalcification for 2 weeks in 4 % 
ethylenediaminetetraacetic acid (EDTA) in phosphate-
buffered saline (PBS), samples were dehydrated and 
paraffin-embedded. Five-µm thick longitudinal sections 
through the distal femur were obtained and placed on 
Superfrost+ slides (Menzel, Braunschweig, Germany).
Immunostaining
Immunohistochemical detection of IdU was performed 
as described previously (Kurth et al., 2011), with the 
modification that the secondary antibody was visualised 
using 3,3-diaminobenzidine peroxidase substrate, and 
sections were counterstained with Haematoxylin QS and 
eosin. Double and triple immunofluorescence stainings to 
detect IdU in conjunction with MSC and lineage markers 
were performed using antibodies and optimised protocols 
as reported previously (Kurth et al., 2011). In addition, 
rabbit anti-NG2 (Millipore-Chemicon, Temecula, CA, 
USA, AB5320) was used at 1:100 dilution following 
antigen retrieval by boiling in an EDTA-based buffer 
solution (pH 9) for 30 min, goat anti-mouse osteocalcin 
(AbD serotec 7060-1815) was used at 1:100 dilution 
following antigen retrieval by pepsin (0.5 mg/mL) in 
0.2 N HCl for 30 min, and goat anti-mouse runx2 (Abcam, 
Cambridge, UK; ab102712) was used at 1:50 dilution 
following antigen retrieval by boiling in an EDTA-based 
buffer solution (pH 9) for 30 min. Isotype negative controls 
were included in all immunostainings to exclude non-
specific antibody binding. Sections were mounted using 
Mowiol containing 4’,6-diamidino-2-phenylindole (DAPI) 
for nuclear counterstaining. Images were acquired from 
the perichondrial groove of Ranvier, the metaphysis and 
diaphysis of the periosteum using a Zeiss (Jena, Germany) 
Imager fluorescence microscope equipped with a Zeiss 
ApoTome, or a Zeiss LSM700 laser-scanning confocal 
microscope. Representative images are shown.
Quantification of labelled cells
A minimum of 3 sections per mouse from 3 mice underwent 
immunofluorescence staining for IdU and the MSC marker 
p75, chosen because it is not expressed by osteoblasts. 
Nuclei were counterstained with DAPI. From each section, 
a minimum of 3 images of the perichondrial groove of 
Ranvier, the metaphyseal and the diaphyseal periosteum 
were obtained. At least 500 total DAPI-stained cells per 
mouse were counted. Values were expressed as average 
± standard deviation (SD) (n = 3) of the percentage of IdU 
positive cells, p75 positive cells or IdU/p75 double-positive 
cells within the total number of DAPI-counterstained cells, 
and the percentage of IdU/p75 double-positive cells within 
the IdU positive cells or the p75 positive cells.
Results
Nucleoside-label-retaining cells are present 
throughout mouse periosteum
To detect nucleoside-label-retaining cells in mouse 
periosteum, three-week-old male C57Bl/6 mice were 
given the nucleoside analogue IdU for 30 days followed 
by a 40-day washout period. We opted to perform the 
labelling assay in young, rapidly growing, mice to increase 
specificity of the assay in the distinction between long-
term label-retaining slow-cycling (stem) cells and the 
cells that instead proliferate extensively to support animal 
growth. IdU was then detected by immunohistochemistry 
in longitudinal sections through the distal femur (Fig. 1A). 
Three anatomical areas of periosteum were distinguished, 
namely the periosteum lining the perichondrial groove of 
Ranvier, the metaphyseal periosteum, and the diaphyseal 
periosteum. IdU+ cells were detected scattered in all 
three areas of the periosteum with no apparent focal 
concentration (Fig. 1B-D).
Nucleoside-label-retaining cells in periosteum have 
an MSC phenotype
The phenotype of the label-retaining cells in periosteum 
was determined by co-immunostaining for IdU and MSC 
or lineage markers. IdU+ cells were non-endothelial 
and non-haematopoietic, as they were negative for the 
endothelial marker von Willebrand factor (vWF; Fig. 
2A) and the pan-haematopoietic marker CD45 (Fig. 2B), 
respectively. Subsets of IdU+ cells were positive for 
cadherin-11 (Fig. 2C) and vimentin (Fig. 2D), markers 
of mesenchymal/stromal cells (Dou et al., 2012; Guler et 
al., 2012; Kaur et al., 2012). Next, we determined whether 
IdU+ cells in periosteum expressed any of the conventional 
MSC markers, focussing first on markers reported to be 
expressed on either mouse or human uncultured MSCs. 
Stem-cell-associated antigen 1 (Sca-1) and platelet-derived 
growth factor receptor alpha (PDGFRα, also known as 
CD140a) have been described as positive markers to 
identify freshly isolated MSCs from mouse bone marrow 
(Peister et al., 2004; Morikawa et al., 2009). Co-staining 
for IdU and Sca-1 revealed subsets of IdU+ cells expressing 
this MSC marker (Fig. 2E). Similarly, a subset of IdU+ cells 
co-stained for PDGFRα (Fig. 2F). Immunofluorescence 
staining for IdU together with p75, also known as low-
affinity nerve growth factor receptor (LNGFR) or CD271, 
and described as a marker of freshly isolated human bone 
marrow MSCs (Jones et al., 2002; Tormin et al., 2011), 
also revealed double-positive cells in mouse periosteum 
(Fig. 2G). Cells double-positive for IdU and the MSC 
markers Sca-1, PDGFRα, or p75 were frequently found 
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Fig. 1. Detection of nucleoside-label-retaining cells in mouse periosteum. Three-week-old C57Bl/6 mice were given 
the nucleoside analogue IdU for 30 days followed by a 40-day washout period. IdU-labelled cells were then detected 
in histological sections of the distal femur by immunohistochemistry. (A) Brightfield image acquired at 250x original 
magnification showing an overview of a longitudinal section through the femur immunostained for IdU. The secondary 
antibody was visualised using 3,3-diaminobenzidine peroxidase substrate (brown) and the section was counterstained 
with haematoxylin and eosin. Bar = 200 μm. (B-D) Higher magnification images of the boxed areas in (A) showing 
IdU-labelled cells (brown) in the periosteum lining the perichondrial groove of Ranvier (B), metaphysis (C), and 
diaphysis (D). Bars = 20 μm.
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F i g .  2 .  P h e n o t y p i c 
c h a r a c t e r i s a t i o n  o f 
nucleoside-label-retaining 
cells in mouse periosteum. 
Three-week-old C57Bl/6 
mice were given the 
nucleoside analogue IdU 
for 30 days followed 
by a 40-day washout 
period. The phenotype 
of IdU-labelled cells in 
the periosteum lining 
the distal  femur was 
determined in histological 
s e c t i o n s  b y  d o u b l e 
immunof luorescence 
staining for IdU (green) 
and MSC/lineage markers 
( r e d ) .  N u c l e i  w e r e 
counterstained with DAPI 
(blue). Representative 
images are shown for the 
endothelial marker vWF 
(A), the haematopoietic 
marker CD45 (B), the 
mesenchymal/stromal 
markers cadherin-11 (C) 
and vimentin (D), and 
the MSC markers Sca-1 
(E), PDGFRα (F), p75 
(G), CD44 (H), CD73 (I) 
and CD105 (J). Arrows 
indica te  IdU s ingle-
positive cells; arrowheads 
indicate marker single-
positive cells; dashed 
arrows indicate IdU and 
marker double-positive 
cells. P: periosteum; B: 
bone. Bars = 20 μm.
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Fig. 3. Determination of nucleoside-label-retention by pericytes in mouse periosteum. Three-week-old C57Bl/6 mice 
(A-C) and a transgenic mouse expressing ß-gal in pericytes and smooth muscle cells (D) were given the nucleoside 
analogue IdU for 30 days followed by a 40-day washout period. Incorporation and retention of IdU by pericytes in 
periosteum was then determined in histological sections of the distal femur by double immunofluorescence staining 
for IdU (green) and the pericyte markers (red) CD146 (A), NG2 (B), and αSMA (C), or ß-gal (D). Nuclei were 
counterstained with DAPI (blue). Arrowhead indicating pericyte marker staining and arrow showing IdU staining. (E 
and F) Triple immunofluorescence staining of distal femur for the pericyte marker CD146 (blue), the MSC marker 
PDGFRα (red) and IdU (green). Nuclei were counterstained with DAPI (white). Yellow arrowhead indicates CD146 
positive cell; yellow arrow shows PDGFRα positive cell; dotted yellow arrow points to IdU+ cell. P: periosteum; B: 
bone. Bars = 20 μm.
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directly adjacent to the bone surface, as well as at some 
distance from the bone (Fig. 2E-G). Finally, expression of 
markers associated with culture-expanded MSCs (Djouad 
et al., 2005; Dominici et al., 2006) was investigated. CD44 
(Fig. 2H) and CD73 (Fig. 2I) were found to be expressed 
by a subset of IdU+ cells located mostly close to the bone 
surface. In addition, IdU+ cells were found positive for 
CD105 (Fig. 2J). Similar patterns of phenotypic marker 
expression by IdU+ cells were found throughout the areas 
of periosteum analysed (i.e., perichondrial groove of 
Ranvier, metaphysis, and diaphysis).
Fig. 4. Nucleoside-label-retention by osteoprogenitors and osteoblasts in mouse periosteum. Three-week-old C57Bl/6 
mice were given the nucleoside analogue IdU for 30 days followed by a 40-day washout period. Incorporation and 
retention of IdU by osteoprogenitors and osteoblasts in periosteum was then determined in histological sections of the 
distal femur by double immunofluorescence staining for the osteoblast markers (red) Runx2 (A) or osteocalcin (D) 
and IdU (green). Nuclei were counterstained with DAPI (blue). Arrows indicate IdU single-positive cells; arrowheads 
indicate marker single-positive cells; dashed arrows indicate IdU and marker double-positive cells. Detection of 
osteoprogenitor marker expression by MSC marker positive cells (B and C) by double immunofluorescence staining 
for the early osteoblast marker Runx2 (green), the MSC marker p75 or PDGFRα (red). Nuclei were counterstained 
with DAPI (blue). Arrows indicate Runx2 single positive cells, arrowheads indicate MSC marker single positive cells 
and dashed arrows indicate Runx2 and MSC marker double positive cells. Triple immunofluorescence staining (E) 
for osteocalcin (red), IdU (green) and p75 (blue). Nuclear counterstaining is not shown for clarity. Arrows indicate 
IdU single-positive cells; arrowheads indicate marker single-positive cells; dashed arrows indicate either IdU-marker 
double-positive cells or IdU-osteocalcin double positive cells; no triple-positive cells were detected. P: periosteum; 
B: bone; GP: growth plate. Bars = 20 μm.
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Quantification of labelled cells
For quantitative analysis of the labelled cells in mouse 
periosteum, we opted to use p75 as an MSC marker 
because other conventional markers of MSCs are known 
to be expressed by osteoblasts, e.g., PDGFRα (Finkenzeller 
et al., 2010), CD73 (Takedachi et al., 2011) and CD44 
(Fujii et al., 2003). Cell counts of at least 500 DAPI-
positive cells from at least 3 sections per mouse revealed 
that IdU-positive cells were 45 ±6 %, p75-positive cells 
were 40 ±14 %, and IdU/p75 double-positive cells were 
27 ±10 % of the total DAPI-counterstained cell population. 
The proportion of cells within the IdU-positive cell pool 
that co-stained for the MSC marker p75 was 58 ±15 %. The 
proportion of cells, within the p75-labelled cell population, 
positive for IdU was 68 ±13 %. These results indicate 
that the MSC marker p75 was not specifically expressed 
by IdU-positive cells, because there were cells that were 
positive for p75 but negative for IdU. In addition, p75 
staining did not identify all IdU-positive cells.
Nucleoside-label-retaining cells in periosteum do not 
express pericyte markers
In recent years, studies have suggested that MSCs in 
various tissues reside in a perivascular niche and form part 
of the pericyte compartment (Sacchetti et al., 2007; Crisan 
et al., 2008). Therefore, the question whether the label-
retaining cells in mouse periosteum expressed pericyte 
markers was investigated. As expected, cells positive for 
the pericyte markers CD146 and NG2 were detected in a 
perivascular location. However, the CD146+ and NG2+ 
cells had not incorporated or failed to retain the nucleoside 
label as they were negative for IdU (Fig. 3A,B). Similarly, 
alpha smooth muscle actin (α-SMA), expressed by human 
pericytes surrounding venules and arterioles (Crisan et 
al., 2008) and recently proposed as a marker of osteo-
chondroprogenitor cells in mice (Grcevic et al., 2012), 
did not co-localise with IdU (Fig. 3C). To further confirm 
these findings, IdU labelling and detection was performed 
in a transgenic mouse in which β-galactosidase (β-gal) 
is expressed in pericytes and smooth muscle cells. This 
transgenic mouse line was generated by random insertional 
mutagenesis and the specific regulatory elements driving 
the expression of LacZ in these mice have not been 
identified (Tidhar et al., 2001). IdU was not detected in 
β-gal-expressing cells in periosteum (Fig. 3D). These 
data indicate that in periosteum long-term label-retaining 
cells, at least partly displaying an MSC-like phenotype, 
may be distinct from pericytes. To clarify the relationship 
between MSCs and pericytes in periosteum, we performed 
triple immunofluorescence staining for PDGFRα, CD146 
and IdU (Fig. 3E,F). CD146+ pericytes associated with 
the vasculature were negative for PDGFRα. However, 
CD146 and PDGFRα double-positive cells were observed 
that were not associated with the vasculature. These cells 
did not stain for IdU, although detection of IdU was sub-
optimal under the conditions used.
Subsets of nucleoside-label-retaining cells are 
osteoblasts that are distinct from MSCs
Nucleoside-label-retention in vivo is a hallmark of stem 
cells, due to their slow-cycling nature. However, cells 
that differentiate into a mature, post-mitotic cell type may 
also retain the nucleoside label. Results shown in Fig. 
2A,B indicated that IdU+ cells were not of the endothelial 
or haematopoietic lineages, respectively. To investigate 
whether IdU+ cells were of the osteoblastic lineage, co-
immunostainings for IdU and osteoblast markers were 
performed. Runx2, a key transcription factor expressed 
early during osteogenic differentiation, was detected in 
subsets of IdU+ cells (Fig. 4A), and Runx2 positive cells 
co-stained for the MSC markers p75 or PDGFRα, with 
no specific topographic distribution across the thickness 
of the periosteum (Fig. 4B,C). Co-staining for IdU and 
osteocalcin, a marker of mature osteoblasts, revealed the 
presence of double-positive cells which were typically 
in direct contact with the periosteal surface (Fig. 4D). In 
addition, osteocytes embedded within the cortical bone were 
found positive for IdU (Fig. 1). Triple immunofluorescence 
staining for IdU in conjunction with p75 as an MSC marker 
and osteocalcin as an osteoblast marker did not reveal any 
triple positive cells (Fig. 4E), confirming the presence of 
distinct populations of label-retaining cells with either an 
MSC or an osteoblastic phenotype.
Discussion
It is widely established that periosteum contains stem/
progenitor cells that play important roles in bone 
regeneration/repair. However, lack of specific markers has 
hindered studies identifying and characterising these cells 
in their native tissue. In this study, a classical long-term 
nucleoside-label-retaining assay was used to identify stem 
cells in mouse periosteum based on their slow-cycling 
nature combined with phenotypic marker expression. The 
findings reported here demonstrate the existence of label-
retaining cells in periosteum with a phenotype compatible 
with MSCs.
 Label-retaining cells were found in the distal femur of 
three-month-old mice throughout the areas of periosteum 
analysed, i.e. at the level of the growth plate, metaphysis 
and diaphysis. This is at odds with a recent study in 
rabbits in which label-retaining cells were found to be 
concentrated in the perichondrial groove of Ranvier 
(Karlsson et al., 2009). This discrepancy may reflect 
species or age differences, as in the Karlsson study BrdU 
was administered to sexually mature rabbits from 3 months 
of age, while in the present study IdU was administered 
to mice from 3 weeks of age, during active bone growth. 
At time of analysis the mice were around 13 weeks of 
age, but periosteal bone apposition continues at this age 
through direct membranous ossification to widen the bone. 
The presence of a large proportion of label-retaining cells 
throughout periosteum may thus reflect a high rate of 
periosteal bone formation in these mice. Our quantification 
data also suggests the heterogeneity of the slow-cycling 
cells in mouse periosteum as not all IdU-positive cells were 
positive for the MSC marker p75. Here we used p75 as 
the only MSC marker because other MSC markers such 
as PDGFRα (Finkenzeller et al., 2010), CD73 (Takedachi 
et al., 2011) and CD44 (Fujii et al., 2003) are reported to 
be also expressed by osteoblasts.
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 In our study, we observed a similar distribution of slow-
cycling cells throughout the periosteum, irrespective of 
their anatomical location. One reason could be the young 
age of the mice during the nucleoside labelling. It may be 
that there is an active contribution of MSCs from all over 
the periosteum to growth.
 Irrespective of the anatomical area, IdU-retaining 
cells were frequently located close to the bone surface, 
presumably within the cambium layer. This is consistent 
with the known presence of osteo-chondroprogenitor 
cells in the cambium layer of the periosteum (Tonna and 
Cronkite, 1962; Ito et al., 2001). Extensive phenotypic 
marker analyses demonstrated the existence of IdU-
retaining cells in periosteum with a phenotype compatible 
with MSCs. Similar to our recent study in synovium (Kurth 
et al., 2011), none of the MSC markers tested labelled all 
the IdU-retaining cells and all markers tested also labelled 
IdU-negative cells.
 Of note, IdU+ cells in periosteum were found positive 
for CD105, an established marker of human MSCs in 
culture (Dominici et al., 2006). This finding is in contrast 
to synovium, where we previously failed to detect IdU-
retaining cells expressing CD105 (Kurth et al., 2011). This 
could reflect an interesting phenotypic or even functional 
difference between MSCs from these two tissues, although 
we cannot exclude the possibility that CD105 labelled (an)
other label-retaining cell type(s) within periosteum. In this 
regard, CD105 is also expressed by endothelial cells but 
the undetectable co-staining between IdU and vWF would 
make an endothelial nature of IdU+CD105+ cells unlikely.
 Nucleoside-label-retaining assays can, in addition to 
slow-cycling stem cells, also label mature, post-mitotic 
cell types. Indeed, epiphyseal chondrocytes were found 
labelled with IdU. Labelling of chondrocytes was most 
notable towards the outer edges of the growth plate. These 
findings are consistent with the Karlsson study (Karlsson 
et al., 2009) and are in keeping with the view that cells 
in the perichondrial groove of Ranvier may act as stem/
progenitor cells for epiphyseal chondrocytes during bone 
growth (Shapiro et al., 1977), a view that is supported 
by the observation that removal of the perichondrial 
groove of Ranvier results in impaired longitudinal bone 
growth (Rodriguez et al., 1985). In addition, subsets of 
osteoblasts in periosteum and osteocytes in cortical bone 
were found positive for the nucleoside label. However, 
label-retaining osteoblasts were negative for the MSC 
marker p75, confirming that at least part of the MSC-like 
label-retaining cells that were identified were distinct from 
osteoblasts. In the adult skeleton, MSCs in periosteum may 
continuously replenish a pool of short-lived osteoblasts 
contributing to bone remodelling and repair throughout life, 
as was recently demonstrated in bone marrow (Park et al., 
2012). In addition to providing a reservoir of precursors for 
mature skeletal cells, MSCs may also play essential roles 
in maintaining the periosteal stroma/vasculature, similar 
to MSCs found in bone marrow (Sacchetti et al., 2007; 
Mendez-Ferrer et al., 2010).
 Increasing evidence suggests that MSCs reside in a 
perivascular niche in various tissues and organs and form 
part of the pericyte compartment (Shi and Gronthos, 2003; 
Dellavalle et al., 2007; Sacchetti et al., 2007; Crisan et al., 
2008; Feng et al., 2011; Grcevic et al., 2012). Therefore, 
the question whether the label-retaining cells in periosteum 
displayed a pericyte phenotype was investigated. Under 
the experimental conditions used, very little or no co-
localisation was detected between IdU and the pericyte 
markers CD146, NG2 and α-sma, nor with β-gal in a 
transgenic mouse in which this reporter gene is expressed 
by pericytes and smooth muscle cells. We previously 
obtained similar findings in mouse synovium, where we 
further demonstrated that pericytes, in contrast to label-
retaining MSCs, did not proliferate in response to joint 
surface injury, indicating these cells did not behave like 
MSCs, at least in this model (Kurth et al., 2011).
 The findings of the current study seem at odds with a 
recent study by Grcevic et al. (2012) who demonstrated 
through lineage tracing that progeny of α-sma+ cells give 
rise to trabecular osteoblasts during normal bone formation 
and to both chondrocytes and osteoblasts during fracture 
repair (Grcevic et al., 2012). Although it seems intuitive 
that in the study by Grcevic et al. progeny of α-sma+ cells 
in periosteum contributed to the formation and subsequent 
remodelling of the fracture callus, their periosteal origins 
remain to be proven. It is possible that labelled progeny of 
α-sma+ cells in the fracture callus were derived from bone 
marrow or other tissues. An alternative explanation may 
be that different populations of MSCs exist in periosteum, 
some of which are pericytes or are derived from pericytes, 
but that this population of pericyte-like MSCs had not 
efficiently incorporated and/or retained the nucleoside 
label in our study due to differences in cycling rates.
 It appears from our data that there may be tissue 
heterogeneity in the contribution of pericytes to the MSC 
pool. This is supported by a study showing that only a 
minority of odontoblasts originate from pericytes, both 
during tooth development and in response to injury (Feng 
et al., 2011). The paradigm that has emerged in recent 
years of the pericyte origin of MSCs may thus not be 
universally applicable to all tissues or experimental models. 
The relative contributions from the pericyte compartment 
to the MSC pool may reflect distinct ontogeny paths of 
MSCs in different tissues, and/or tissue-specific functions 
of MSC-like cells, such as the support of the perivascular 
haematopoietic stem cell (HSC) niche and sinusoidal 
network in bone marrow (Sacchetti et al., 2007; Méndez-
Ferrer et al., 2010,).
 The topography of periosteal MSCs is largely unknown, 
but earlier reports based on morphological analysis of 
label-retaining cells (Tonna and Cronkite et al., 1962) 
and analysis of cartilage formation in periosteal explant 
cultures (Ito et al., 2001) suggested that cells in periosteum 
closest to the bone surface are more differentiated, 
committed progenitors, while undifferentiated stem cells 
reside in the area of the cambium layer that is farthest from 
the bone. This is an attractive model, as it would suggest 
a flow of stem/progenitor cells from the outer cambium 
inward, with progressively increased levels of lineage 
commitment/differentiation as the cells migrate closer to 
the bone, until they give rise to mature osteoblasts residing 
on the periosteal surface. However, the phenotypic marker 
analyses carried out in the current study revealed the 
presence of label-retaining cells expressing MSC markers 
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in close proximity to bone. These findings appear not in 
keeping with the earlier proposed model, although one 
possible explanation could be that the nucleoside labelling 
scheme used in the present study, in addition to labelling 
MSCs, may have labelled committed progenitors that still 
express some MSC markers. In support of this, we detected 
Runx2 positive osteoprogenitors, which were also positive 
for the MSC markers p75 or PDGFRα.
 Adult stem cells are traditionally considered to 
be slow-cycling, label-retaining cells that give rise to 
transit-amplifying progenitor cells which in turn give 
rise to daughter cells that differentiate into mature 
cell types. However, in the haematopoietic system, 
significant heterogeneity exists in the cycling rates of 
otherwise phenotypically identical HSCs. Recent studies 
demonstrated that under homeostatic conditions, around 
one-fifth of HSCs proliferate at an extremely low rate, 
estimated at ≤ 0.8-1.8 % per day (Foudi et al., 2009), 
or around once every 145 days (Wilson et al., 2008). 
Dormant and active HSCs are thought to reside in distinct 
topographical niches in the bone marrow, namely the 
endosteal and perivascular niche, respectively (Celso and 
Scadden, 2011). Similarly, increasing evidence indicates 
that dormant and active stem cells co-exist in other adult 
tissues, including the intestinal crypts, the bulge of the hair 
follicle, and possibly the subventricular zone of the brain, 
in adjacent but distinct niches (Greco and Guo, 2010; Li 
and Clevers, 2010). It is postulated that quiescent stem cells 
with very low cycling rates represent a population of the 
most primitive, undifferentiated stem cells which ensure 
lifelong maintenance of the stem cell compartment, while 
faster cycling stem cells are responsible for supplying the 
continuous pool of progenitor cells required for normal 
tissue turnover.
 It is tempting to speculate that, similar to other stem 
cell types, MSCs may be heterogeneous in their cycling 
rates under homeostatic conditions. If the most dormant, 
undifferentiated MSCs cycle at similar rates as the most 
dormant HSC population currently identified (i.e., around 
once every 4-5 months (Wilson et al., 2008; Foudi et al., 
2009), the label-retaining assay employed in the current 
study would have failed to label the majority of these cells.
 Furthermore, it has been postulated that stem cells, 
during asymmetric cell division, retain the original set 
of DNA strands while the newly synthesised strands are 
passed on to differentiating daughter cells. This is known 
as the immortal strand hypothesis (Cairns, 1975). Such 
non-random segregation of DNA strands would alter the 
interpretation of the label-retaining assays. However, 
although some evidence in support of the immortal strand 
hypothesis exists in other stem cell types, it remains unclear 
whether this applies to all stem cells in all tissues (Yadlapalli 
et al., 2008). In addition, it is currently not known under 
what conditions MSCs divide asymmetrically. Therefore, 
whether we have identified the most primitive stem cells 
remains to be clarified.
 In conclusion, we have identified and phenotypically 
characterised label-retaining cells in mouse periosteum 
and have demonstrated the existence of label-retaining 
cells with a phenotype compatible with MSCs. Further 
studies will be required to demonstrate whether the model 
described above, i.e. that the most primitive MSCs are 
located furthest from bone, may hold true. Such studies 
will shed light on the spatial and temporal relationships 
between MSCs, progenitors, and mature cell types, in 
periosteum and indeed other tissues. A full understanding 
of the biology of multipotent stem/progenitor cells in 
periosteum is critical for the development of improved 
protocols and discovery of novel pharmacological targets 
to maintain bone homeostasis throughout life and stimulate 
bone regeneration and repair.
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Discussion with Reviewers
I. Khan: Therapeutic applications utilising periosteal 
MSCs are likely to require in vitro expansion; can the 
phenotype, and thus their efficacy, be retained in vitro? And 
in this regard, to what extent are the in vivo non-cellular 
components of the periosteum integral to the phenotype 
of the periosteal MSCs and can we draw lessons for in 
vitro expansion?
Authors: We agree with the reviewer that the therapeutic 
use of periosteal MSCs is likely to require in vitro 
expansion, while ensuring that phenotype and potency 
of the MSCs are maintained. Our study identifying label-
retaining MSCs in the periosteum is a first step towards 
a better understanding of the native MSCs at their niche 
sites. The investigation of niche components with emphasis 
onto the extracellular matrix could elucidate the type of 
environment that would be needed for three-dimensional 
in vitro expansion of periosteal MSCs to ensure they 
maintain their original phenotype and function. This would 
enhance consistency of bioprocessing of periosteal MSCs 
for clinical use.
I. Khan: It is interesting that the periosteal MSC 
population may be distinct from the pericytes. Could there 
be a potential mechanistic relationship between periosteal 
MSCs and the pericytes in bone formation (or fracture 
healing) with the pericytes supporting osteogenesis via 
vascularisation? If so, would therapeutic applications 
benefit from dual-cell implantation?
Authors: A potential mechanistic relationship between 
periosteal MSCs and the pericytes in bone formation 
or repair with the pericytes supporting osteogenesis via 
vascularisation is fascinating and requires investigation. 
Vascularisation is an important feature of bone formation/
repair, and there is evidence that endothelial cells can 
enhance bone formation (Grellier et al., 2009, additional 
reference). Dual implantation of pericytes and MSCs could 
thus be beneficial since pericytes are known to play an 
important role in vascularisation.
Additional Reference
 Grellier M, Bordenave L, Amédée J (2009) Cell-to-
cell communication between osteogenic and endothelial 
lineages: implications for tissue engineering. Trends 
Biotechnol. 27: 562-571.
